“BeiGene announced positive top-line data for tislelizumab (PD-1) in relapsed/ refractory classical Hodgkin’s lymphoma (R/R cHL) from its China-based study which now positions the company to file an NDA in China later in 2018. Concurrently, BeiGene announced fast-track designation for BTK inhibitor zanubrutinib and plans for potential submission of an NDA in 1H19 in the US for Waldenstrom macroglobulinemia (WM) based on previously announced P1 data.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.8% and a 45.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BeiGene Ltd with a $212.50 average price target, which is a 25.6% upside from current levels. In a report released today, Piper Jaffray also reiterated a Buy rating on the stock with a $200 price target.
Based on BeiGene Ltd’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $105 million. In comparison, last year the company had a GAAP net loss of $60.8 million.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).